Shed, a modern wellness company focused on helping individuals feel and function their best, announces the launch of several new products designed to provide affordable, weight management support options for individuals at every stage of their...
enGene Holdings Inc. a clinical-stage, non-viral gene-based immunotherapy company, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also...
Kashiv BioSciences, LLC announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The randomized, double-blind, multicenter study...
Exobiosphere S.à r.l. and Space Cargo Unlimited today announced the signing of a Memorandum of Understanding (MoU) during the Paris Air Show to launch joint space missions focused on high-throughput biotechnology research. High-throughput...
The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a new Team Science Award and an Early Career...
Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics...
Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform. iXCells’ mission is to empower...
Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult...
Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced an exclusive agreement with Agios Pharmaceuticals Inc. A...
CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics,...
Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single...
Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, today announced its participation. "A major...
Biodextris, a leading Contract Development and Manufacturing Organization (CDMO) rooted in the legacy of GSK's biologics and vaccine operations and backed by the healthcare-focused private equity firm ArchiMed, is proud to announce the appointment...
Samsung Bioepis Co., Ltd. and Organon & Co. announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration...
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Doxycycline for Injection, USP in the United States as a therapeutic generic equivalent for DOXY 100®, as approved by the...
Eden, the leading health platform connecting individuals with licensed providers and pharmacies focused on metabolic health, today announced expanded access to a pharmacy-grade compounded glutathione injection protocol. The therapy is now...
Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials. Epinephrine Injection 30 mg per 30 mL is a prescription medicine used...
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab)....
Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, announced it has secured a $5 million grant from the French government to accelerate the advancement and scaling up of Eligo's proprietary topical...